Given these results and the similar toxicity profiles observed with monotherapy in stages III/IV and IIB/IIC melanoma, combination adjuvant immunotherapy involving anti-CTLA4 and anti-PD-1 therapies could cause serious adverse effects in stage II settings. Here, CTLA4 is linked to melanoma.